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Purpose of the study
Antiretroviral (ARV) toxicity, especially of nucleoside-ana-
logues, together with HIV-infection have both been dem-
onstrated to induce mitochondrial DNA (mtDNA)
depletion and mitochondrial dysfunction. The contribu-
tion of each mechanism (either HIV or ARV) to the
observed mitochondrial damage present in HIV-infected
patients on highly active ARV treatment (HAART) is diffi-
cult to elucidate. HIV-induced mitochondrial lesion has
been studied in HIV-infected but non-HAART-treated
individuals, but ARV-related mitochondrial damage has
been poorly explored in non-infected subjects. The aim of
the present study is to assess in vivo mitochondrial toxic-
ity of HAART without HIV-infection effects.
Methods
We included six healthy patients under one month of pro-
phylactic ARV treatment consisting of FTC+TDF+SQVr to
prevent HIV-infection after risk exposure. All of them
remained uninfected 6 months after HAART withdrawal.
Mitochondrial studies were performed in mononuclear
cells before and after the ARV treatment to assess mtDNA
content using real time PCR and mitochondrial function
trough the spectrophotometric measurement of the enzy-
matic activity of both mitochondrial respiratory chain
(MRC) complex II (non-mitochondrial encoded) and
complex IV (partially encoded in the mitochondrial
genome). Statistical analysis compared mitochondrial
results before and after ARV therapy by the t-test for
repeated measures.
Summary of results
Mitochondrial DNA content was 20% reduced along the
ARV treatment in the studied patients (2.17+2.52 a
1.73+1.01, p = 0.5). MRC complex IV enzymatic activity
was 24% reduced in these subjects after HAART
(55.2+15.9 a 42+6.3, p = 0.1), although MRC complex II
enzymatic activity remained unchanged after therapy dis-
continuation and with respect to baseline (26.5+10.5 a
27.8+9.4, p = 0.98).
Conclusion
In non-HIV-infected patients, one month of ARV treat-
ment induced mitochondrial damage, even when consid-
ering the HAART consisting of FTC+TDF+SQV/r with
theoretical low mitochondrial toxic profile. Mitochon-
drial changes consisted of slight mtDNA depletion and
moderated mtDNA-encoded-MRC complex IV dysfunc-
tion, although none of these changes were statistically sig-
nificant. These findings validate HAART-induced
mitochondrial toxicity, even in the absence of HIV infec-
tion. Further studies should be performed to assess mito-
chondrial toxicity of different HAART schedules in non-
infected individuals to elucidate toxic effects of antiretro-
virals without HIV or previous ARV interference.
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